Drug intelligence / Profile preview

GT90008

Development stage: Unknown
Lead developer: Kintor Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GT90008 is an investigational **PD-L1/TGF-β dual-targeting antibody** being developed by **Kintor Pharmaceutical** for cancer immunotherapy, with rights in Greater China licensed from **Gensun**. Public company disclosures describe it as a biologic antibody with high activity against both **PD-L1** and **TGF-βR2**, intended to simultaneously block immune checkpoint signaling and TGF-β pathway-mediated immunosuppression in the tumor microenvironment. It has been reported in clinical development for **advanced solid tumors** in China, where an NMPA clinical trial approval was announced in 2021.

Targets

TGFBR2 (TGF-β receptor type 2)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on GT90008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT90008.

Explore the full profile